Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on...
Clinical Trial
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial...
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the...
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new...
BRTX-100 Front and Center at ORS 2025
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health”...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen...
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended...
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental...
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
AI Revolutionizing Industries: Market Set for 39.7% CAGR Growth, Reaching $1.1 Trillion by 2029
"From Healthcare and Life Sciences to Oil & Gas and Diagnostics, BCC Research Highlights How AI is Transforming Industries, Enhancing...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of...
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on...
GCCL Wins 2025 Asia-Pacific Customer Value Leadership Award by Frost & Sullivan
- GCCL's "One-Stop Lab Solution" sets the industry benchmark with unmatched competitiveness and a dedication to global excellence. - Continuing...
Sibel Health’s AI-powered wearable reduces nighttime scratching in itchy patients
Published in Journal of American Medical Association (JAMA) Dermatology, Sibel's advanced wearable sensor coupled with biofeedback led to a 40% decrease...
Transforming Patient Recruitment: myTomorrows Introduces Next-Generation AI Platform for Precision Trial Matching
With the goal of streamlining industry-wide clinical trial recruitment and improving patient outcomes, myTomorrows unveils its next major AI-powered technological...
PhaseV to Present AI Advances in Clinical Development Optimization at Upcoming Biotech and Data Science Events
Presentations Will Demonstrate Effective Use of Machine Learning and Adaptive Clinical Trial Design to Enhance Precision and Efficiency in Drug...
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated...
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...